| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Insider buying and selling activity across 114 companies in the Pharmaceuticals industry. Part of the Health Care sector.
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Apr 3, 2020 | LLY Eli Lilly & Co | Lilly Endowment Inc | 10% Owner | Sell | 26,723 | $143.19 | $3,826,492.98 | - | |
| Apr 2, 2020 | ALKS Alkermes Plc. | Pops Richard F57 | Director And CEO, Alkermes Plc | Sell | 50,000 | $13.79 | $689,500.00 | -6.2% | |
| Apr 2, 2020 | LLY Eli Lilly & Co | Lilly Endowment Inc | 10% Owner | Sell | 166,038 | $140.78 | $23,374,653.56 | - | |
| Apr 1, 2020 | AMPH Amphastar Pharmaceuticals, Inc. | Petersen Floyd F.51 | Director | Sell | 500 | $14.36 | $7,181.30 | -0.7% | |
| Apr 1, 2020 | BUDZ Weed, Inc. | Breen Nicole M | 10% Owner | Sell | 173,992 | $0.27 | $46,790.01 | - | |
| Mar 31, 2020 | LLY Eli Lilly & Co | Lilly Endowment Inc | 10% Owner | Sell | 38,962 | $140.07 | $5,457,473.58 | - | |
| Mar 30, 2020 | LLY Eli Lilly & Co | Fry Stephen F | SVP, Hr &Diversity | Sell | 14,657 | $134.30 | $1,968,434.40 | -3.3% | |
| Mar 30, 2020 | LLY Eli Lilly & Co | Lilly Endowment Inc | 10% Owner | Sell | 210,000 | $139.11 | $29,213,558.67 | - | |
| Mar 26, 2020 | ALKS Alkermes Plc. | Pops Richard F57 | Director And CEO, Alkermes Plc | Sell | 75,000 | $14.36 | $1,077,225.00 | -9.0% | |
| Mar 24, 2020 | ALKS Alkermes Plc. | Landine Michael J | SVP, Corp Dev., Alkermes, Inc. | Sell | 25,000 | $13.91 | $347,717.50 | -11.0% | |
| Mar 19, 2020 | ALKS Alkermes Plc. | Pops Richard F57 | Director And CEO, Alkermes Plc | Sell | 75,000 | $14.47 | $1,085,427.60 | -3.1% | |
| Mar 18, 2020 | AMRX Amneal Pharmaceuticals, Inc. | Meister Paul M | Director | Buy | 353,649 | $2.74 | $970,343.91 | +236.7% | |
| Mar 17, 2020 | ALKS Alkermes Plc. | Landine Michael J | SVP, Corp Dev., Alkermes, Inc. | Sell | 25,000 | $13.54 | $338,506.33 | -5.8% | |
| Mar 17, 2020 | TEVA Teva Pharmaceutical Industries Ltd | Daniell Richard | Exec. VP, European Commercial | Sell | 616 | $7.17 | $4,417.58 | -5.6% | |
| Mar 17, 2020 | TEVA Teva Pharmaceutical Industries Ltd | Nazzi Gianfranco | EVP, International Markets | Sell | 345 | $7.17 | $2,474.13 | -1.7% | |
| Mar 17, 2020 | TEVA Teva Pharmaceutical Industries Ltd | Stark David Matthew53 | Exec. VP Chief Legal Officer | Sell | 2,359 | $7.16 | $16,898.70 | -44.2% | |
| Mar 17, 2020 | TEVA Teva Pharmaceutical Industries Ltd | O'Grady Brendan P. | EVP, North America Commercial | Sell | 470 | $7.16 | $3,366.85 | -3.1% | |
| Mar 17, 2020 | TEVA Teva Pharmaceutical Industries Ltd | Fridriksdottir Hafrun47 | Executive VP, Global R&D | Sell | 514 | $7.16 | $3,682.04 | -0.6% | |
| Mar 17, 2020 | TEVA Teva Pharmaceutical Industries Ltd | Griffin Deborah A | Chief Accounting Officer | Sell | 944 | $7.16 | $6,762.34 | -100% | |
| Mar 16, 2020 | EBS Emergent Biosolutions Inc. | Harsanyi Zsolt | Director | Sell | 6,400 | $65.00 | $416,000.00 | -17.6% | |
| Mar 16, 2020 | LLY Eli Lilly & Co | Norton Johna | Senior VP, Global Quality | Sell | 4,727 | $131.00 | $619,237.00 | -21.1% | |
| Mar 16, 2020 | AQST Aquestive Therapeutics, Inc. | Boyd Peter E.84 | Svp-bus. Process &Info. Tech. | Buy | 2,000 | $1.50 | $3,000.00 | +4.0% | |
| Mar 16, 2020 | AQST Aquestive Therapeutics, Inc. | Braender Lori J | SVP, General Counsel | Buy | 14,000 | $1.54 | $21,624.40 | +127.3% | |
| Mar 16, 2020 | ORGO Organogenesis Holdings Inc. | Avista Capital Managing Member Iv, LLC | Director, 10% Owner | Buy | 542,349 | $3.98 | $2,160,956.66 | +0.5% | |
| Mar 13, 2020 | JNJ Johnson & Johnson | Perez William D | Director | Buy | 500 | $127.69 | $63,843.00 | +3.2% |
The blue line has two modes, toggled with the Relative and Absolute buttons:
Relative (default) shows cumulative industry performance with both the overall market and parent sector movements removed. When the line rises above 100, the industry is outperforming its sector; below 100 means underperforming. This is calculated using factor returns via weighted least squares (WLS) regression, isolating pure industry-specific behavior.
Absolute shows the total cumulative return of the industry including market and sector movement. This reflects what an investor actually experienced — an industry can show strong absolute gains even while underperforming its sector in relative terms.
Both views start at an index of 100. Other return drivers such as momentum, value, or size are deliberately retained in both modes, since these are part of what makes an industry behave the way it does and may reflect the conditions insiders are responding to.